Safety and outcome of bedaquiline and delamanid-based longer oral regimen in Indian children less than 5 years with drug-resistant tuberculosis
BDQ and DLM-based regimens appear effective and generally well tolerated in treating DR-TB in children under 5. However, a longer course of treatment of over 18 months is required. Careful monitoring for side effects, especially QTc prolongation, remains critical.
Authors
- Minnie Bodhanwala (ORCID: https://orcid.org/0000-0002-3301-3858)
- Dhruv Gandhi
- Daksha Shah
- Varsha Puri
- Suhani Jain (ORCID: https://orcid.org/0000-0001-9574-9580)
- Sanjay K. Mattoo
- Ira Shah
- Ramsha Ansari
Institutions
- National Tuberculosis Institute (IN)
- Maharashtra State Board of Technical Education (IN)
- Bai Jerbai Wadia Hospital for Children (IN)
- New Delhi Tuberculosis Center (IN)
Publication Details
- Journal
- Lung India
- Published
- 2025-12-31
- DOI
- https://doi.org/10.4103/lungindia.lungindia_266_25
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00